PMEF
HAE icon

Point72 Middle East FZE’s Haemonetics HAE Stock Holding History

Point72 Middle East FZE’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,506
Closed -$590K – 1855
2022
Q4 		$590K Buy
+7,506
New +$603K 0.03% 673

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's HAE Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 7,506 shares — an estimated $590K sold.

Point72 Middle East FZE first reported a position in HAE in Q4 2022 and held it in 1 quarter. The position peaked at $590K in Q4 2022. 301 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 7,506 Haemonetics shares in Q1 2023, an estimated $590K.
  • Point72 Middle East FZE first reported a position in Haemonetics in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Haemonetics position peaked at $590K in Q4 2022.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.